SIC
JAZZ icon

SJS Investment Consulting’s Jazz Pharmaceuticals JAZZ Stock Holding History

SJS Investment Consulting’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150K Buy
795
+38
+5% +$6.64K 0.02% 171
2025
Q4 		$129K Hold
757
– – 0.02% 176
2025
Q3 		$99.8K Hold
757
– – 0.01% 187
2025
Q2 		$80.3K Sell
757
-5
-0.7% -$543 0.01% 143
2025
Q1 		$94.6K Buy
762
+1
+0.1% +$130 0.02% 143
2024
Q4 		$93.7K Buy
761
+1
+0.1% +$118 0.02% 141
2024
Q3 		$84.7K Buy
760
+2
+0.3% +$219 0.01% 150
2024
Q2 		$80.9K Sell
758
-2
-0.3% -$220 0.02% 137
2024
Q1 		$91.5K Buy
760
+3
+0.4% +$367 0.02% 137
2023
Q4 		$93.1K Sell
757
-1
-0.1% -$125 0.02% 128
2023
Q3 		$98.1K Buy
758
+2
+0.3% +$266 0.02% 110
2023
Q2 		$93.7K Sell
756
-1
-0.1% -$135 0.02% 109
2023
Q1 		$111K Sell
757
-3
-0.4% -$444 0.03% 102
2022
Q4 		$121K Buy
760
+5
+0.7% +$733 0.04% 104
2022
Q3 		$101K Buy
+755
New +$115K 0.03% 117
2022
Q1 		$117K Buy
752
+2
+0.3% +$290 0.04% 124
2021
Q4 		$96K Buy
+750
New +$98.6K 0.03% 129

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SJS Investment Consulting's JAZZ Position: Q1 2026 in Review

SJS Investment Consulting increased its Jazz Pharmaceuticals (JAZZ) stake by 5% in Q1 2026, buying an estimated $6.64K and bringing the position to 795 shares worth $150K. The position accounts for 0.02% of the portfolio, ranked #171.

SJS Investment Consulting first reported a position in JAZZ in Q4 2021 and has held it in 17 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • SJS Investment Consulting held 795 shares of Jazz Pharmaceuticals worth $150K as of Q1 2026.
  • SJS Investment Consulting bought 38 Jazz Pharmaceuticals shares in Q1 2026, an estimated $6.64K.
  • Jazz Pharmaceuticals made up 0.02% of SJS Investment Consulting's portfolio in Q1 2026, its #171 holding.
  • SJS Investment Consulting first reported a position in Jazz Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.